Indoleamine 2,3-dioxygenase expression in chronic myelogenous leukemia patients: association with disease progression (2005)
- Authors:
- USP affiliated authors: MENDES, JOAO GUSTAVO PESSINI AMARANTE - ICB ; CASTRO, FABÍOLA ATTIÉ DE - FCFRP ; MOREIRA FILHO, CARLOS ALBERTO - ICB
- Unidades: ICB; FCFRP
- Assunto: IMUNOLOGIA
- Language: Inglês
- Imprenta:
- Publisher: Brazilian Society of Immunology
- Publisher place: São Pedro
- Date published: 2005
- Source:
- Título do periódico: Resumos
- Conference titles: Meeting of the Brazilian Society of Immunology
-
ABNT
MARTI, L. et al. Indoleamine 2,3-dioxygenase expression in chronic myelogenous leukemia patients: association with disease progression. 2005, Anais.. São Pedro: Brazilian Society of Immunology, 2005. . Acesso em: 23 abr. 2024. -
APA
Marti, L., Castro, F. A. de, Jacysyn, J. F., Tobo, P. R., Lopes, L. R., Hamerschlak, N., et al. (2005). Indoleamine 2,3-dioxygenase expression in chronic myelogenous leukemia patients: association with disease progression. In Resumos. São Pedro: Brazilian Society of Immunology. -
NLM
Marti L, Castro FA de, Jacysyn JF, Tobo PR, Lopes LR, Hamerschlak N, Zanichelli MA, Candido DLA, Okamoto OK, Amarante-Mendes JGP, Moreira-Filho CA. Indoleamine 2,3-dioxygenase expression in chronic myelogenous leukemia patients: association with disease progression. Resumos. 2005 ;[citado 2024 abr. 23 ] -
Vancouver
Marti L, Castro FA de, Jacysyn JF, Tobo PR, Lopes LR, Hamerschlak N, Zanichelli MA, Candido DLA, Okamoto OK, Amarante-Mendes JGP, Moreira-Filho CA. Indoleamine 2,3-dioxygenase expression in chronic myelogenous leukemia patients: association with disease progression. Resumos. 2005 ;[citado 2024 abr. 23 ] - Expression of pro-apoptotic bid and bik genes is decreased in chronic myeloid leukemia and low levels of bik MRNA are associated with lack of response to imatinib treatment
- Down regulation of Hematopoietic SH2 domain containing (HSH2D) in the progression of the chronic myelogenous leukemia
- Correlation between metabolic alterations and apoptosis resistance confered by BCR-ABL expression
- Genomic approach to understand the mechanisms invilved in Bcr-Abl-mediated resistance to apoptosis
- Conversion of CD95 (Fas) type II into type I signaling by sub-lethal doses of cycloheximide
- Development and characterization of murine models of T lymphoma to investigate the impact of oncogene expression
- Cosmomycin D, an anthracycline more potent than Doxorubicin for induction of tumor cell death, synergize with imatinib mesilate to induce apoptosis in Bcr-Abl-positive cells
- T lymphoma murine models to study the impact of ectopic expression of anti-apoptotic oncogenes
- BH3 mimetics and TKI combined therapy for Chronic Myeloid Leukemia
- Study of pro and anti-apoptotic genes to understand the resistance of apoptosis mediated by Bcr-Abl
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
